UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000009871
Receipt number R000011567
Scientific Title Phase II study of continuation maintenance by use of TS1 and Bevacizumab after induction chemotherapy of cisplatin and TS1 pulse bevacizumab in patients with Stage IIIB / IV non-squamous and non-small cell lung cancer - Research of efficacy predictive biomarker
Date of disclosure of the study information 2013/01/31
Last modified on 2018/09/29 16:31:49

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II study of continuation maintenance by use of TS1 and Bevacizumab after induction chemotherapy of cisplatin and TS1 pulse bevacizumab in patients with Stage IIIB / IV non-squamous and non-small cell lung cancer - Research of efficacy predictive biomarker

Acronym

Phase II of cisplatin and TS1 pulse bevacizumab followed by TS1 and bevacizumab

Scientific Title

Phase II study of continuation maintenance by use of TS1 and Bevacizumab after induction chemotherapy of cisplatin and TS1 pulse bevacizumab in patients with Stage IIIB / IV non-squamous and non-small cell lung cancer - Research of efficacy predictive biomarker

Scientific Title:Acronym

Phase II of cisplatin and TS1 pulse bevacizumab followed by TS1 and bevacizumab

Region

Japan


Condition

Condition

Non-small and non-squamous cell lung cancer

Classification by specialty

Pneumology Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate efficacy and safety of cisplatin and TS1 pulse bevacizumab followed by TS1 and bevacizumab in patients with Stage IIIB / IV non-squamous and non-small cell lung cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Phase II


Assessment

Primary outcomes

Progression free survival from the beginning of maintenance therapy

Key secondary outcomes

Response rate by RECIST, Overall survival, Time to treatment failure,
Adverse events, Quality of life, Efficacy predictive factors (Thymidylate synthase, Dihydoropyrimidine dehydrogenase, others)


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Cisplatin and TS1 pulse bevacizumab followed by TS1 and bevacizumab

the other trial of same chemotherapy without bevacizumab at same time

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

I) Eligibility criteria for Pre-registration
1) Histologically or cytologically proven non-squamous and non-small cell lung cancer
2) Stage IIIB/IV without indication for radical thoracic irradiation or recurrence after surgical treatment
3) Naive treatment of cytotoxic chemotherapy.
Treatments below are acceptable for pre-registaration
a) Palliative Irradiation except primary tumor of lung more than 2 weeks ago
b)First line treatment by epidermal growth factor receptor-tyrosine kinase inhibitors more than 2 weeks ago
c)post-operation adjuvant therapy more than 6 months.
4)Eastern Cooperative Oncology Group performance status of 0-1
5)Age; > or = 20 years and < 75 years
6) Tumor has the evaluable lesion.
7) capable of oral intake
8) Adequate organ function, Adequate organ function within 2 weeks
a) Leukocyte count; > or = 3,000/mm3
b) Neutrophil count; > or = 1,500/mm3
c) Platelet count; > or = 100,000/mm3
d) Hemoglobin concentration; > or = 10.0g/dl
e) Total bilirubin level; < or = 2.0 mg/dl
f) Aspartate aminotransferse and alanine aminotransferase levels; < or = 100 IU/L
g) PaO2; > or = 60 Torr or SpO2; > or = 90% at room air
h) Creatinine clearance; > or = 60mL/min
9) Estimating Survival more than 12 weeks
10)Written informed consent

II) Eligibility Criteria for registration
1) More than 2 cycles of induction chemotherapy
2) Response criteria of induction chemotherapy achieved more than and equal to SD.
3) Maintenance can start within 6 weeks after start of TS1 of last cycle.

Key exclusion criteria

1) Patients with squamous cell lung cancer.
2) History of allergic reaction for agents of present treatment
3) Severe myelosupperssion, renal dysfunction or hepatic dysfunction
4) Patients received post-operation adjuvant therapy within 6 months.
5) Active concomitant malignancy except carcinoma in situ, intramucosal carcinoma or cancer with more than 5 year disease free
6) Significant comorbid disease such as paresis of intestine, ileus, interstitial pneumonia, lung fibrosis, uncontrolled diabetes mellitus, cardiac failure, renal failure, hepatic failure, active gastrointestinal ulcer, myocardial infarction and angina pectoris within 6 months, other uncontrolled disease
7) Diarrhea more than and equal to grade 2
8) Active infection more than and equal to grade 2
9) Massive pleural effusion, peritoneal effusion or cardiac effusion required for tube drainage
10) Symptomatic brain metastasis but eligible for controlled brain metastases
11) Patients required for continuing steroid therapy
12) A history of significant hemoptysis (> 2.5 mL red blood per episode) within 3 months before enrolment
13) History of thrombosis
14) Surgical biopsy or treatment within 4 weeks
15) Under treatment of oral coagulant or intravenous coagulant
16) Bleeding tendency, blood coagulation disorder
17) Other ineligible for bevacizumab
18) Pregnant status or lactation
19) Uncontrolled psychiatric disease
20) Other ineligible status judged by medical oncologist.

Target sample size

33


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yuichiro Takeda

Organization

National Center for Global health and Medicine

Division name

Department of Respiratory Medicine

Zip code


Address

1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan

TEL

03-3202-7181

Email

ytakeda@hosp.ncgm.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yuichiro Takeda

Organization

National Center for Global health and Medicine

Division name

Department of Respiratory Medicine

Zip code


Address

1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan

TEL

03-3202-7181

Homepage URL


Email

ytakeda@hosp.ncgm.go.jp


Sponsor or person

Institute

Department of Respiratory Medicine
National Center for Global health and Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

None


Other related organizations

Co-sponsor

None

Name of secondary funder(s)

None


IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立国際医療研究センター病院(東京都)


Other administrative information

Date of disclosure of the study information

2013 Year 01 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2012 Year 10 Month 17 Day

Date of IRB


Anticipated trial start date

2012 Year 12 Month 17 Day

Last follow-up date

2018 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 01 Month 25 Day

Last modified on

2018 Year 09 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011567


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name